
    
      This is an open-label extension study for subjects who participated in the control arm of
      study #09-1 (A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the
      EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately
      Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents) who are not treatment
      failures and completed 12 months of the study.
    
  